Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-12-01T06:30:17.508Z Has data issue: false hasContentIssue false
  • English
  • Français

2966 – Understanding the Non-adherence and how to Improve it

Published online by Cambridge University Press:  15 April 2020

P.-M. Llorca
P.-M. Llorca*
Affiliation:
University of Auvergne, Clermont-Ferrand, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Schizophrenia is a chronic psychiatric disorder with onset of symptoms typically occurring in early adulthood, and requires lifelong treatment. Treatment goals for the long-term management of this debilitating disorder include sustained symptom remission and control, maintaining or improving patient level of functioning and quality of life, prevention of relapse, and continued monitoring for adverse events, as well as sustained adherence to medication.1 Poor adherence to medication is multifactorial and presents a major challenge in the long-term management of schizophrenia. in fact, rates of non-adherence and of partial compliance to antipsychotic medication are high and are associated with a significantly increased risk of relapse, hospitalization, and the potential for progressive functional impairment, resulting in increased morbidity and high healthcare costs.2,3 Thus, recognizing and managing non-adherence with the latest treatment advances has the potential to benefit patients as well as their families.

One possible solution to the challenge of non-adherence is the availability of long-acting injectable (LAI) formulations of atypical antipsychotics. The use of LAI antipsychotics may help improve the management of adherence and enhance the therapeutic alliance through regular injection visits. in addition to pharmacotherapy, current clinical practice guidelines recommend the use of psychoeducation to improve treatment outcomes.4 Psychoeducation, along with other behavioral therapies, can facilitate the improvement of patient insight, prevention of relapse, promotion of adherence, and ultimately improve continuity of care.

This presentation will provide an overview of key unmet needs in the long-term management of schizophrenia, and evaluate factors leading to non-adherence. The use of non-pharmacological and pharmacological strategies for improving adherence in routine clinical practice will be discussed in the context of a strong therapeutic alliance.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E1783
Copyright
Copyright © European Psychiatric Association 2013

References

References:

Falkai, P., et al.World Federation of Societies of Biological Psychiatry (wfsbp) Guidelines For Biological Treatment of Schizophrenia, Part 2: Long-term Treatment of Schizophrenia. World J Biol Psychiatry 2006; 7: 5–40CrossRefGoogle Scholar
Weiden, P.J., et al.Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients with Schizophrenia. Psychiatr Serv 2004; 55: 886–891CrossRefGoogle Scholar
Llorca, P.M. Partial Compliance in Schizophrenia and The Impact on Patient Outcomes. Psychiatry Res 2008; 161: 235–247CrossRefGoogle Scholar
National Institute for Health and Clinical Excellence. Schizophrenia core interventions in the treatment and management of schizophrenia in primary and secondary care. Available at: http://www.nice.org.uk/nicemedia/live/11786/43608/43608.pdf (January 2013).Google Scholar
Submit a response

Comments

No Comments have been published for this article.